Press Releases Better Therapeutics, Inc.

Equities

BTTX

US08773T1043

Market Closed - OTC Markets Other stock markets 01:03:21 29/06/2024 am IST			5-day change	1st Jan Change
0.0125 ^USD	+13.64%		+86.57%	-93.59%

22/05	Click Therapeutics, Inc. acquired Assets of Better Therapeutics, Inc..	CI
21/03	Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.	23/05	AQ
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq	14/03	BU
Better Therapeutics : Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq - Form 8-K	14/03	PU
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers	05/03	BU
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)	04/03	BU
Transcript: Better Therapeutics CEO Interview with RedChip - Form 8-K	04/03	PU
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease	20/02	BU
Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment	06/02	BU
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone	17/01	BU
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States	03/01	BU
Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease	02/01	BU
Better Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	18/12	PU
Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions	28/11	BU
Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award	14/11	BU
Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates	09/11	BU
Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023	08/11	BU
Better Therapeutics : Results of Operations and Financial Condition - Form 8-K	31/23/31	PU
Better Therapeutics to participate in the American College of Lifestyle Medicine's 2023 Annual Conference	27/23/27	AQ
Better Therapeutics to Participate in the American College of Lifestyle Medicine’s 2023 Annual Conference	26/23/26	BU
Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes	16/23/16	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Better Therapeutics, Inc.

Equities

BTTX

US08773T1043

Press Releases

Filters